Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 9/20 | 0.61 |
| ▸ | ACLY | P53396 | 3/20 | 0.60 |
| ▸ | SGK1 | O00141 | 2/20 | 0.53 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.48 |
| ▸ | CCR4 | P51679 | 2/20 | 0.46 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5090048 | 0.87 | PTGES2 (0.51) | PTGES2ACLYSGK1 | |
| SCHEMBL2146100 | 0.85 | MCL1 (0.51) | PTGES2ACLYSLC40A1BRD4 | |
| SCHEMBL1265337 | 0.84 | PTGES2 (0.64) | PTGES2ACLYSGK1SLC40A1FSCN1 | |
| SCHEMBL13875348 | 0.84 | PTGES2 (0.70) | PTGES2ACLYSGK1SLC40A1CCR4 | |
| SCHEMBL7852262 | 0.81 | PTGES2 (0.68) | PTGES2ACLYSGK1SLC40A1CCR4 | |
| SCHEMBL1265855 | 0.80 | PTGES2 (0.56) | PTGES2ACLYSGK1SLC40A1BRD4 | |
| SCHEMBL2145893 | 0.80 | MCL1 (0.64) | ACLYSGK1SLC40A1 | |
| SCHEMBL9464640 | 0.78 | ACLY (0.62) | ACLY | |
| SCHEMBL30897292 | 0.76 | PTGES2 (0.61) | PTGES2ACLYSGK1SLC40A1CCR4 | |
| SCHEMBL3787762 | 0.76 | PTGES2 (1.00) | PTGES2ACLYSGK1SLC40A1CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521725-B1 | ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-11-27 | — | — | EP | disclosed |
| US-20130178472-A1 | ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-07-11 | — | — | US | disclosed |
| EP-2521725-A1 | ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011083275-A1 | ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178472-A1 | ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF | NDUFS2, NDUFS6, NDUFS3 | PTGES2 2519/4885ACLY 362/4885SGK1 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.